Australia, Aug. 12 -- Incyte Holdings Corp., owns the trademark (2472435) for 'INCYTE' till April 23, 2034.
Status: protected:
Registered/protected
Classes: 5 [Pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the treatment of immunological disorders; pharmaceutical preparations for the treatment of auto-immune disorders; pharmaceutical preparations for the treatment of inflammatory disorders; pharmaceutical preparations for the treatment of graft versus host disorder (GVHD); pharmaceutical preparations for the treatment of hematological disorders; pharmaceutical preparations for the treatment of myeloproliferative disorders; pharmaceutical preparations for the treatment of skeletal or chondrocyte disorders; pharmaceutical preparations for the treatment of dermatological disorders.] and 42 [Scientific and medical research relating to oncological, viral, hematological, auto-immune, graft versus host, inflammatory, metabolic, myeloproliferative, skeletal or chondrocyte and dermatological disorders.]
Type of Mark: Word
Date of Acceptance: June 3
Registration Advertised: Aug. 11
For further details contact Minter Ellison Rudd Watts and Frances M. Jagla Christensen O'Connor Johnson Kindness.
The original document can be viewed at: https://search.ipaustralia.gov.au/trademarks/search/view/2472435.
Disclaimer: Curated by HT Syndication.
